|Endpoint||Unadjusted||Adjusted Model 1∗||Adjusted Model 2†|
|OR/HR||p Value||OR/HR||p Value||OR/HR||p Value|
|Baseline Cystatin C|
|Death at 30 days||2.46||<0.01||2.14||0.01||1.44||0.42|
|Death/recurrent hospital stay at 30 days||1.61||<0.01||1.74||<0.01||0.81||0.49|
|Death at 180 days||2.07||<0.01||1.70||<0.01||0.86||0.59|
|Improved dyspnea at 6 h||0.86||0.26||0.96||0.84||0.98||0.93|
|Improved dyspnea at 24 h||0.70||0.03||0.72||0.16||0.77||0.40|
|Death or worsening heart failure prior to discharge||2.09||<0.01||2.28||<0.01||1.04||0.93|
|Length of stay‡∗||0.74||<0.01||0.75||<0.01||0.85||0.10|
|Length of stay‡∗ (high vs. low)||1.88||<0.01||1.86||<0.01||1.45||0.08|
|Follow-up (48- to 72-h) Cystatin C|
|Death at 30 days||2.63||<0.01||2.91||0.13||2.25||0.26|
|Death/recurrent hospital stay at 30 days||1.65||<0.01||1.31||0.45||1.27||0.53|
|Death at 180 days||2.07||<0.01||1.37||0.33||1.30||0.43|
|Length of stay‡∗||0.81||<0.01||1.05||0.68||1.02||0.91|
|Length of stay‡∗ (high vs. low)||1.63||<0.01||0.93||0.79||1.00||0.99|
ASCEND-HF = Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure; BUN = blood urea nitrogen; HR = hazard ratio; OR = odds ratio.
↵∗ Adjusted model 1 = covariates derived from overall ASCEND-HF population excluding BUN and creatinine.
↵† Adjusted model 2 = covariates derived from overall ASCEND-HF population including BUN and creatinine.
↵‡ For length of stay, numerically lower hazard ratio equates to high risk for increased length of stay.